ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Aging-Driven Inter-Organ Crosstalk in Postmenopausal Osteoporosis: From Immunometabolic Drift to Multisystem Frailty.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Macrophage metabolic reprogramming via HIF-1α-glycolysis drives osteoblast ferroptosis and bone loss through an IL-6-STAT3-dependent redox axis.Redox report : communications in free radical research · 2026Article
- A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.Current osteoporosis reports · 2026Review
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
- Osteoimmunological impacts of micro/nanoplastics: systemic translocation, inflammatory responses, and bone remodeling disruption.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMOP) is increasingly recognized as an aging-associated, multisystem vulnerability state in which estrogen withdrawal amplifies immune and metabolic drift across bone marrow, muscle, adipose tissue, the gut, vasculature, and neural circuits. We synthesize evidence that key control nodes including RANKL-RANK-OPG imbalance, Th17/Treg disequilibrium, loss of regulatory B cell IL-10 restraint, inflammatory myeloid polarization, and expansion of bone marrow adipose tissue encode persistent osteoclastogenic tone and impaired formation. We map how microbiota-derived metabolites and barrier dysfunction tune osteoimmunity, and how exercise-responsive myokines and metabolites can counteract drift. Extracellular vesicles emerge as bidirectional couriers that propagate senescence and inflammation or support repair, but clinical translation requires ISEV-aligned methodological rigor and robust manufacturing, biodistribution, and safety frameworks. Building on these inter-organ axes, we propose a phenotype-aware "network reset" roadmap that integrates antifracture therapy with functional restoration, falls prevention, cardiometabolic risk control, and inflammatory monitoring, prioritizing composite endpoints and real-world implementation infrastructure. This systems framing shifts PMOP management from bone-only correction toward coordinated restoration of whole-body resilience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.